Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Potential Benefits Targets three metabolic pathways simultaneously (GLP-1, GIP, glucagon), addressing both appetite and energy expenditure in a way single and dual-agonist agents cannot Strong appetite control and satiety support through combined GLP-1 and GIP receptor activation, including central hypothalamic satiety signaling Hepatic fat oxidation and increased resting energy expenditure through glucagon receptor activation: the layer that distinguishes retatrutide from semaglutide and tirzepatide Studied for significant weight reduction in phase 2 clinical trials: the highest-dose group in the NEJM 2023 trial lost an average of approximately 24% of body weight at 48 weeks (controlled-trial average
When the medicine is eventually approved, prescribers will follow the MHRA-approved Summary of Product Characteristics
BPC-157 contributes cytoprotection and VEGFR2-mediated angiogenesis
Loading phase: MT-I 1-3 sprays daily, MT-II 1-2 sprays daily for 2-4 weeks
